Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Ramucirumab Biosimilar - Anti-VEGFR-2 mAb - Research Grade |
---|---|
Source | DrugBank DB05578 |
Species | Human |
Expression system | Mammalian cells |
Molecular weight | 143kDa |
Purity | >95% |
Buffer | PBS pH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | Ramucirumab |
Reference | PX-TA1023-SIL |
Related Products | PX-P3059 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1Kappa |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Formula | C6374H9864N1692O1996S46 |
Ramucirumab is a monoclonal antibody. Monoclonal antibodies are created in a lab to attach to the targets found on specific types of cancer cells. The antibody calls the immune system to attack the cell it is attached to, resulting in the immune system killing the cell. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth or other functions necessary for cell growth. Ramucirumab inhibits the activity of vascular endothelial growth factor (VEGF). VEGF is responsible for angiogenesis, or the development of new blood vessels by and for the tumor (or any tissue), so blocking VEGFs activity prevents the growth of new blood vessels, essentially cutting off the tumor’s source of nutrients. This product is for research use only.
Reviews
Il n’y a pas encore d’avis.